Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancerCancer Diagnostic

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223490

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223490

APAC Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 455 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

Asia Pacific uterine cancer diagnostics market is projected to register a CAGR of 10.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia Pacific uterine cancer diagnostics market are:

Increasing uterine cancer patients among the women population

Rise in technological advancement for uterine cancer diagnostic

Market Players

The key market players operating in the Asia Pacific uterine cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare Private Limited

Narang Medical Limited

ESAOTE SPA

Olympus Corporation

Integra LifeSciences

Canon Medical Systems ANZ Pty Limited.

KARL STORZ SE & Co. KG

Stryker

Guzip Biomarkers Corporation

General Electric Company

FUJIFILM Corporation

Koninklijke Philips N.V.

B. Braun SE

Jalal Surgical

Show more

TABLE OF CONTENTS

1 INTRODUCTION 117

  • 1.1 OBJECTIVES OF THE STUDY 117
  • 1.2 MARKET DEFINITION 117
  • 1.3 OVERVIEW OF THE ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET 117
  • 1.4 CURRENCY AND PRICING 119
  • 1.5 LIMITATIONS 119
  • 1.6 MARKETS COVERED 119

2 MARKET SEGMENTATION 127

  • 2.1 MARKETS COVERED 127
  • 2.2 GEOGRAPHICAL SCOPE 128
  • 2.3 YEARS CONSIDERED FOR THE STUDY 129
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 130
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 133
  • 2.6 MULTIVARIATE MODELLING 134
  • 2.7 MARKET APPLICATION COVERAGE GRID 135
  • 2.8 INSTRUMENT BASED LIFELINE CURVE 136
  • 2.9 DBMR MARKET POSITION GRID 137
  • 2.10 VENDOR SHARE ANALYSIS 139
  • 2.11 SECONDARY SOURCES 140
  • 2.12 ASSUMPTIONS 140

3 EXECUTIVE SUMMARY 141

4 PREMIUM INSIGHTS 144

  • 4.1 PESTEL ANALYSIS 145
  • 4.2 PORTER'S FIVE FORCES 146
  • 4.3 PATENT ANALYSIS OF ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET 147
  • 4.4 REIMBURSEMENT SCENARIO 148
  • 4.5 INDUSTRY INSIGHTS: 149
  • 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 149
  • 4.7 PRICING STRATEGIES 149
  • 4.8 CONCLUSION 150
  • 4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 151
  • 4.10 COST OF UTERINE CANCER PROCEDURE 153

5 REGULATORY FRAMEWORK 154

6 MARKET OVERVIEW 156

  • 6.1 DRIVERS 158
    • 6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 158
    • 6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 158
    • 6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 159
    • 6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 159
  • 6.2 RESTRAINTS 160
    • 6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 160
    • 6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 160
  • 6.3 OPPORTUNITIES 161
    • 6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 161
    • 6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 161
    • 6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 162
  • 6.4 CHALLENGES 162
    • 6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 162
    • 6.4.2 HIGH COST OF IMAGING SYSTEMS 163

7 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 164

  • 7.1 OVERVIEW 165
  • 7.2 INSTRUMENT-BASED 168
    • 7.2.1 ULTRASOUND SCANNING 169
      • 7.2.1.1 SYSTEMS 169
      • 7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 170
      • 7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 170
      • 7.2.1.4 ACCESSORIES 170
    • 7.2.2 IMAGING DEVICES 170
      • 7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 171
      • 7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 171
      • 7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 171
      • 7.2.2.4 OTHERS 171
    • 7.2.3 TESTS 172
      • 7.2.3.1 BLOOD TESTS 172
        • 7.2.3.1.1 COMPLETE BLOOD COUNT 172
        • 7.2.3.1.2 CA125 MARKER BLOOD TEST 172
      • 7.2.3.2 URINE TESTS 173
      • 7.2.3.3 OTHER TESTS 173
    • 7.2.4 OTHERS 173
  • 7.3 PROCEDURE BASED 173
    • 7.3.1 ENDOMETRIAL BIOPSY 174
    • 7.3.2 HYSTEROSCOPY 174
    • 7.3.3 DILATION & CURETTAGE 174
    • 7.3.4 CYSTOSCOPY 174
    • 7.3.5 PROCTOSCOPY 175
    • 7.3.6 OTHERS 175

8 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 176

  • 8.1 OVERVIEW 177
  • 8.2 ENDOMETRIAL CANCER 180
    • 8.2.1 SEROUS ADENOCARCINOMA 181
      • 8.2.1.1 INSTRUMENT-BASED 181
        • 8.2.1.1.1 ULTRASOUND SCANNING 182
        • 8.2.1.1.2 IMAGING DEVICES 182
        • 8.2.1.1.3 TESTS 182
        • 8.2.1.1.4 OTHERS 182
      • 8.2.1.2 PROCEDURE-BASED 183
        • 8.2.1.2.1 ENDOMETRIAL BIOPSY 183
        • 8.2.1.2.2 HYSTEROSCOPY 183
        • 8.2.1.2.3 DILATION & CURETTAGE 183
        • 8.2.1.2.4 CYSTOSCOPY 183
        • 8.2.1.2.5 PROCTOSCOPY 183
        • 8.2.1.2.6 OTHERS 184
    • 8.2.2 ADENOSQUAMOUS CARCINOMA 184
      • 8.2.2.1 INSTRUMENT-BASED 184
        • 8.2.2.1.1 ULTRASOUND SCANNING 184
        • 8.2.2.1.2 IMAGING DEVICES 185
        • 8.2.2.1.3 TESTS 185
        • 8.2.2.1.4 OTHERS 185
      • 8.2.2.2 PROCEDURE-BASED 185
        • 8.2.2.2.1 ENDOMETRIAL BIOPSY 185
        • 8.2.2.2.2 HYSTEROSCOPY 185
        • 8.2.2.2.3 DILATION & CURETTAGE 186
        • 8.2.2.2.4 CYSTOSCOPY 186
        • 8.2.2.2.5 PROCTOSCOPY 186
        • 8.2.2.2.6 OTHERS 186
    • 8.2.3 UTERINE CARCINOSARCOMA 186
      • 8.2.3.1 INSTRUMENT-BASED 186
        • 8.2.3.1.1 ULTRASOUND SCANNING 187
        • 8.2.3.1.2 IMAGING DEVICES 187
        • 8.2.3.1.3 TESTS 187
        • 8.2.3.1.4 OTHERS 187
      • 8.2.3.2 PROCEDURE-BASED 188
        • 8.2.3.2.1 ENDOMETRIAL BIOPSY 188
        • 8.2.3.2.2 HYSTEROSCOPY 188
        • 8.2.3.2.3 DILATION & CURETTAGE 188
        • 8.2.3.2.4 CYSTOSCOPY 188
        • 8.2.3.2.5 PROCTOSCOPY 188
        • 8.2.3.2.6 OTHERS 189
    • 8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 189
      • 8.2.4.1 INSTRUMENT-BASED 189
        • 8.2.4.1.1 ULTRASOUND SCANNING 189
        • 8.2.4.1.2 IMAGING DEVICES 190
        • 8.2.4.1.3 TESTS 190
        • 8.2.4.1.4 OTHERS 190
      • 8.2.4.2 PROCEDURE-BASED 190
        • 8.2.4.2.1 ENDOMETRIAL BIOPSY 190
        • 8.2.4.2.2 HYSTEROSCOPY 190
        • 8.2.4.2.3 DILATION & CURETTAGE 191
        • 8.2.4.2.4 CYSTOSCOPY 191
        • 8.2.4.2.5 PROCTOSCOPY 191
        • 8.2.4.2.6 OTHERS 191
  • 8.3 UTERINE SARCOMA 191
    • 8.3.1 LEIOMYOSARCOMA 192
      • 8.3.1.1 INSTRUMENT-BASED 192
        • 8.3.1.1.1 ULTRASOUND SCANNING 193
        • 8.3.1.1.2 IMAGING DEVICES 193
        • 8.3.1.1.3 TESTS 193
        • 8.3.1.1.4 OTHERS 193
      • 8.3.1.2 PROCEDURE-BASED 194
        • 8.3.1.2.1 ENDOMETRIAL BIOPSY 194
        • 8.3.1.2.2 HYSTEROSCOPY 194
        • 8.3.1.2.3 DILATION & CURETTAGE 194
        • 8.3.1.2.4 CYSTOSCOPY 194
        • 8.3.1.2.5 PROCTOSCOPY 194
        • 8.3.1.2.6 OTHERS 195
    • 8.3.2 ENDOMETRIAL STROMAL SARCOMA 195
      • 8.3.2.1 INSTRUMENT-BASED 195
        • 8.3.2.1.1 ULTRASOUND SCANNING 195
        • 8.3.2.1.2 IMAGING DEVICES 196
        • 8.3.2.1.3 TESTS 196
        • 8.3.2.1.4 OTHERS 196
      • 8.3.2.2 PROCEDURE-BASED 196
        • 8.3.2.2.1 ENDOMETRIAL BIOPSY 196
        • 8.3.2.2.2 HYSTEROSCOPY 196
        • 8.3.2.2.3 DILATION & CURETTAGE 197
        • 8.3.2.2.4 CYSTOSCOPY 197
        • 8.3.2.2.5 PROCTOSCOPY 197
        • 8.3.2.2.6 OTHERS 197
    • 8.3.3 UNDIFFERENTIATED SARCOMA 197
      • 8.3.3.1 INSTRUMENT-BASED 198
        • 8.3.3.1.1 ULTRASOUND SCANNING 198
        • 8.3.3.1.2 IMAGING DEVICES 198
        • 8.3.3.1.3 TESTS 198
        • 8.3.3.1.4 OTHERS 198
      • 8.3.3.2 PROCEDURE-BASED 199
        • 8.3.3.2.1 ENDOMETRIAL BIOPSY 199
        • 8.3.3.2.2 HYSTEROSCOPY 199
        • 8.3.3.2.3 DILATION & CURETTAGE 199
        • 8.3.3.2.4 CYSTOSCOPY 199
        • 8.3.3.2.5 PROCTOSCOPY 200
        • 8.3.3.2.6 OTHERS 200

9 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 201

  • 9.1 OVERVIEW 202
  • 9.2 >60 YEARS 205
  • 9.3 51-60 YEARS 206
  • 9.4 41-50 YEARS 207
  • 9.5 31-40 YEARS 208
  • 9.6 <30 YEARS 209

10 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 210

  • 10.1 OVERVIEW 211
  • 10.2 HOSPITALS 214
  • 10.3 DIAGNOSTIC CENTERS 215
  • 10.4 CANCER RESEARCH CENTERS 216
  • 10.5 AMBULATORY SURGICAL CENTERS 217
  • 10.6 SPECIALIZED CLINICS 218
  • 10.7 OTHERS 219

11 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 220

  • 11.1 OVERVIEW 221
  • 11.2 DIRECT TENDER 224
  • 11.3 THIRD PARTY DISTRIBUTORS 225
  • 11.4 OTHERS 226

12 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 227

  • 12.1 ASIA-PACIFIC 228
    • 12.1.1 CHINA 245
    • 12.1.2 JAPAN 258
    • 12.1.3 INDIA 271
    • 12.1.4 AUSTRALIA 284
    • 12.1.5 TAIWAN 297
    • 12.1.6 NEW ZEALAND 310
    • 12.1.7 SOUTH KOREA 323
    • 12.1.8 SINGAPORE 336
    • 12.1.9 INDONESIA 349
    • 12.1.10 PHILIPPINES 362
    • 12.1.11 VIETNAM 375
    • 12.1.12 THAILAND 388
    • 12.1.13 MALAYSIA 400
    • 12.1.14 REST OF ASIA PACIFIC 413

13 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 414

  • 13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 414

14 SWOT ANALYSIS 415

15 COMPANY PROFILE 416

  • 15.1 KONINKLIJKE PHILIPS N.V. 416
    • 15.1.1 COMPANY SNAPSHOT 416
    • 15.1.2 REVENUE ANALYSIS 416
    • 15.1.3 COMPANY SHARE ANALYSIS 417
    • 15.1.4 PRODUCT PORTFOLIO 417
    • 15.1.5 RECENT DEVELOPMENTS 417
  • 15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 419
    • 15.2.1 COMPANY SNAPSHOT 419
    • 15.2.2 COMPANY SHARE ANALYSIS 419
    • 15.2.3 PRODUCT PORTFOLIO 420
    • 15.2.4 RECENT DEVELOPMENTS 420
  • 15.3 GENERAL ELECTRIC COMPANY 421
    • 15.3.1 COMPANY SNAPSHOT 421
    • 15.3.2 REVENUE ANALYSIS 421
    • 15.3.3 COMPANY SHARE ANALYSIS 422
    • 15.3.4 PRODUCT PORTFOLIO 422
    • 15.3.5 RECENT DEVELOPMENTS 422
  • 15.4 SIEMENS HEALTHCARE GMBH 424
    • 15.4.1 COMPANY SNAPSHOT 424
    • 15.4.2 REVENUE ANALYSIS 424
    • 15.4.3 COMPANY SHARE ANALYSIS 425
    • 15.4.4 PRODUCT PORTFOLIO 425
    • 15.4.5 RECENT DEVELOPMENTS 425
  • 15.5 FUJIFILM CORPORATION 426
    • 15.5.1 COMPANY SNAPSHOT 426
    • 15.5.2 REVENUE ANALYSIS 426
    • 15.5.3 COMPANY SHARE ANALYSIS 427
    • 15.5.4 PRODUCT PORTFOLIO 427
    • 15.5.5 RECENT DEVELOPMENTS 427
  • 15.6 AED.MD 429
    • 15.6.1 COMPANY SNAPSHOT 429
    • 15.6.2 PRODUCT PORTFOLIO 429
    • 15.6.3 RECENT DEVELOPMENTS 429
  • 15.7 ARQUER DIAGNOSTICS LTD 430
    • 15.7.1 COMPANY SNAPSHOT 430
    • 15.7.2 PRODUCT PORTFOLIO 430
    • 15.7.3 RECENT DEVELOPMENTS 430
Show more
  • 15.8 B. BRAUN SE 431
    • 15.8.1 COMPANY SNAPSHOT 431
    • 15.8.2 PRODUCT PORTFOLIO 431
    • 15.8.3 RECENT DEVELOPMENTS 431
  • 15.9 ESAOTE SPA 432
    • 15.9.1 COMPANY SNAPSHOT 432
    • 15.9.2 PRODUCT PORTFOLIO 432
    • 15.9.3 RECENT DEVELOPMENTS 432
  • 15.10 F. HOFFMANN-LA ROCHE LTD 434
    • 15.10.1 COMPANY SNAPSHOT 434
    • 15.10.2 REVENUE ANALYSIS 434
    • 15.10.3 PRODUCT PORTFOLIO 435
    • 15.10.4 RECENT DEVELOPMENTS 435
  • 15.11 GRAIL 436
    • 15.11.1 COMPANY SNAPSHOT 436
    • 15.11.2 PRODUCT PORTFOLIO 436
    • 15.11.3 RECENT DEVELOPMENTS 436
  • 15.12 GUZIP BIOMARKERS CORPORATION 438
    • 15.12.1 COMPANY SNAPSHOT 438
    • 15.12.2 PRODUCT PORTFOLIO 438
    • 15.12.3 RECENT DEVELOPMENTS 438
  • 15.13 INTEGRA LIFESCIENCES 439
    • 15.13.1 COMPANY SNAPSHOT 439
    • 15.13.2 REVENUE ANALYSIS 439
    • 15.13.3 PRODUCT PORTFOLIO 440
    • 15.13.4 RECENT DEVELOPMENTS 440
  • 15.14 JALAL SURGICAL 441
    • 15.14.1 COMPANY SNAPSHOT 441
    • 15.14.2 PRODUCT PORTFOLIO 441
    • 15.14.3 RECENT DEVELOPMENTS 441
  • 15.15 KARL STORZ SE & CO. KG 442
    • 15.15.1 COMPANY SNAPSHOT 442
    • 15.15.2 PRODUCT PORTFOLIO 442
    • 15.15.3 RECENT DEVELOPMENTS 443
  • 15.16 MEDTRONIC 444
    • 15.16.1 COMPANY SNAPSHOT 444
    • 15.16.2 REVENUE ANALYSIS 444
    • 15.16.3 PRODUCT PORTFOLIO 445
    • 15.16.4 RECENT DEVELOPMENTS 445
  • 15.17 NARANG MEDICAL LIMITED 446
    • 15.17.1 COMPANY SNAPSHOT 446
    • 15.17.2 PRODUCT PORTFOLIO 446
    • 15.17.3 RECENT DEVELOPMENTS 446
  • 15.18 OLYMPUS CORPORATION 447
    • 15.18.1 COMPANY SNAPSHOT 447
    • 15.18.2 REVENUE ANALYSIS 447
    • 15.18.3 PRODUCT PORTFOLIO 448
    • 15.18.4 RECENT DEVELOPMENTS 448
  • 15.19 STRYKER 449
    • 15.19.1 COMPANY SNAPSHOT 449
    • 15.19.2 REVENUE ANALYSIS 449
    • 15.19.3 PRODUCT PORTFOLIO 450
    • 15.19.4 RECENT DEVELOPMENTS 450
  • 15.20 SURTEX INSTRUMENTS LIMITED. 451
    • 15.20.1 COMPANY SNAPSHOT 451
    • 15.20.2 PRODUCT PORTFOLIO 451
    • 15.20.3 RECENT DEVELOPMENTS 451

16 QUESTIONNAIRE 452

17 RELATED REPORTS 455

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC RATE OF ENDOMETRIAL CANCER (2020) 81
  • TABLE 2 U.S. (2022) 81
  • TABLE 3 U.K. (2019) 81
  • TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019) 81
  • TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020) 81
  • TABLE 6 SINGAPORE (2020) 81
  • TABLE 7 JAPAN (2022) 81
  • TABLE 8 INDIA (2020) 82
  • TABLE 9 AUSTRALIA (2022) 82
  • TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018) 82
  • TABLE 11 ARGENTINA (2020) 82
  • TABLE 12 UAE (2020) 82
  • TABLE 13 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 14 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
  • TABLE 15 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 16 ASIA PACIFIC ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 17 ASIA PACIFIC ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 99
  • TABLE 18 ASIA PACIFIC SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 19 ASIA PACIFIC SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 100
  • TABLE 20 ASIA PACIFIC IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 21 ASIA PACIFIC IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 101
  • TABLE 22 ASIA PACIFIC TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 23 ASIA PACIFIC BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 24 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
  • TABLE 25 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 26 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 104
  • TABLE 27 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 28 ASIA PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 29 ASIA PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 30 ASIA PACIFIC SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 31 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 32 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 33 ASIA PACIFIC ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 34 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 35 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 36 ASIA PACIFIC UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 37 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 38 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 39 ASIA PACIFIC PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 40 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 41 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 42 ASIA PACIFIC UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 43 ASIA PACIFIC UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 44 ASIA PACIFIC LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 45 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 46 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 47 ASIA PACIFIC ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 48 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 49 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 50 ASIA PACIFIC UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 51 ASIA PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 52 ASIA PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 53 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 134
  • TABLE 54 ASIA PACIFIC >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 55 ASIA PACIFIC 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 56 ASIA PACIFIC 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 57 ASIA PACIFIC 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 58 ASIA PACIFIC <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 59 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 143
  • TABLE 60 ASIA PACIFIC HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
  • TABLE 61 ASIA PACIFIC DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 62 ASIA PACIFIC CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 63 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
  • TABLE 64 ASIA PACIFIC SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 65 ASIA PACIFIC OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 66 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 153
  • TABLE 67 ASIA PACIFIC DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
  • TABLE 68 ASIA PACIFIC THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 155
  • TABLE 69 ASIA PACIFIC OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
  • TABLE 70 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 162
  • TABLE 71 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 72 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 73 ASIA-PACIFIC ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 74 ASIA-PACIFIC ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 163
  • TABLE 75 ASIA-PACIFIC ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 163
  • TABLE 76 ASIA-PACIFIC SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 77 ASIA-PACIFIC SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 163
  • TABLE 78 ASIA-PACIFIC SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 164
  • TABLE 79 ASIA-PACIFIC IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 80 ASIA-PACIFIC IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 164
  • TABLE 81 ASIA-PACIFIC IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 164
  • TABLE 82 ASIA-PACIFIC TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 83 ASIA-PACIFIC BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 84 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 85 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 165
  • TABLE 86 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 166
  • TABLE 87 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
  • TABLE 88 ASIA-PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
  • TABLE 89 ASIA-PACIFIC SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 166
  • TABLE 90 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 91 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 92 ASIA-PACIFIC ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 93 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 94 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 95 ASIA-PACIFIC UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 96 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 97 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 98 ASIA-PACIFIC PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 99 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 100 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 101 ASIA-PACIFIC UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 102 ASIA-PACIFIC LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 103 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 104 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 105 ASIA-PACIFIC ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 106 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 107 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 108 ASIA-PACIFIC UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 109 ASIA-PACIFIC INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 110 ASIA-PACIFIC PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 111 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 173
  • TABLE 112 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 173
  • TABLE 113 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 174
  • TABLE 114 CHINA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 115 CHINA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 116 CHINA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 117 CHINA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 175
  • TABLE 118 CHINA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 176
  • TABLE 119 CHINA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 120 CHINA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 176
  • TABLE 121 CHINA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 176
  • TABLE 122 CHINA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 123 CHINA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 177
  • TABLE 124 CHINA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 177
  • TABLE 125 CHINA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 126 CHINA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 127 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 128 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 178
  • TABLE 129 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 178
  • TABLE 130 CHINA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 131 CHINA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 132 CHINA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 133 CHINA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 134 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 135 CHINA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 136 CHINA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 137 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 138 CHINA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 139 CHINA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 140 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 141 CHINA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 142 CHINA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 143 CHINA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 144 CHINA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 145 CHINA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 183

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 56
  • FIGURE 2 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 59
  • FIGURE 3 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 60
  • FIGURE 4 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 61
  • FIGURE 5 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 61
  • FIGURE 6 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 62
  • FIGURE 7 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID 64
  • FIGURE 8 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 66
  • FIGURE 9 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 68
  • FIGURE 10 ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 72
  • FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 73
  • FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030 73
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET 86
  • FIGURE 14 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022 94
  • FIGURE 15 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION) 95
  • FIGURE 16 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030) 95
  • FIGURE 17 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE 96
  • FIGURE 18 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022 106
  • FIGURE 19 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION) 107
  • FIGURE 20 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030) 107
  • FIGURE 21 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE 108
  • FIGURE 22 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 131
  • FIGURE 23 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 132
  • FIGURE 24 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 132
  • FIGURE 25 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 133
  • FIGURE 26 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022 140
  • FIGURE 27 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 141
  • FIGURE 28 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 141
  • FIGURE 29 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 142
  • FIGURE 30 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 150
  • FIGURE 31 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 151
  • FIGURE 32 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 151
  • FIGURE 33 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 152
  • FIGURE 34 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 158
  • FIGURE 35 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 159
  • FIGURE 36 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 159
  • FIGURE 37 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 160
  • FIGURE 38 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 160
  • FIGURE 39 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 343
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!